The Daily Byte
Breaking
Welcome to The Daily Byte — real stories from across Pakistan.
Saturday, 21 November 2026 · Pakistan

The Daily Byte

Stories from Pakistan that deserve to be heard
Minor Markets

Convatec shares jump 8.9% to lead FTSE 100 after raising sales guidance

By The Daily Byte ·19 Nov 2026 ·4 min read
A nurse in blue scrubs and gloves applying a wound dressing to a patient's forearm in a clinic
Shares in Convatec jumped 8.9% to 268.80p on Wednesday, making the medical products group the best performer in the FTSE 100, after it raised its full-year sales guidance on accelerating growth. The wider FTSE 100 index was down 0.3% on the day. Convatec, which makes wound care, continence care and infusion care products, said in a trading update for the ten months to 31 October 2026 that it now expects full-year organic revenue growth of 6.25% to 7.0%, excluding its InnovaMatrix wound treatment. That is up from previous guidance of 5.5% to 6.5% growth, measured against revenue of $2.44 billion in 2025. ## Growth accelerates in the second half Organic revenue grew 6.6% over the ten-month period excluding InnovaMatrix, and 3.7% including it. Reported revenue growth was 4.8%. Chief executive Jonny Mason said: "Revenue growth has accelerated in the second half, as we expected." The strongest momentum came from Infusion Care, where revenue grew at a double-digit rate over the ten months, driven by faster growth in diabetes in the second half and continued strong growth in AbbVie's treatment for Parkinson's disease. Convatec now expects double-digit growth in the division for the full year, up from high-single-digit guidance previously. Continence Care also improved, and the company raised its full-year expectation for the division to mid-to-high single-digit growth, from mid-single-digit growth before. Advanced Wound Care grew at a low-to-mid single-digit rate excluding InnovaMatrix, broadly in line with the first half, with its ConvaFoam range continuing to gain share. ## InnovaMatrix expectations cut The one weak spot was InnovaMatrix, the wound care treatment whose sales have disappointed. Convatec now expects the product to bring in only about $5 million of revenue in 2026, at the bottom of its previous $5 million to $10 million range. Even so, the company kept its other financial targets unchanged. It still expects an adjusted operating profit margin of at least 23% for the year, despite about 65 basis points of adverse currency effects and a further 90 basis points of pressure from InnovaMatrix, and it still expects double-digit growth in adjusted earnings per share. Analysts at J.P. Morgan said the update should ease concerns about whether Convatec could meet its 2026 forecasts, noting that the step-up in growth needed in the second half had worried investors. With six weeks of the year left, the raised top-line guidance and reiterated margin target should end those concerns, the bank said. ## Buyback and spending plans unchanged Convatec confirmed that its $200 million share buyback remains on track to complete during the 2026 financial year. Full-year capital expenditure is expected to come in at the upper end of its previously announced $200 million to $230 million range, as the company spends more on expanding capacity. The group also reiterated its medium-term targets of 6% to 8% organic revenue growth and double-digit adjusted earnings per share growth, and said it aims to reach an adjusted operating margin in the mid-20s percent range from 2027. ## What this means for investors The upgrade matters because Convatec had been under pressure to show that growth was genuinely picking up rather than simply recovering. A raised revenue forecast, delivered alongside unchanged profit guidance, suggests management believes the acceleration in Infusion Care and Continence Care is durable enough to offset the InnovaMatrix shortfall. The shares remain well below their levels of recent years, and the market will now look to the full-year results for confirmation that the second-half momentum has carried through to profits as well as sales. ## FAQ **What is Convatec?** Convatec is a London-listed medical products and technologies company focused on chronic conditions. Its main divisions are Advanced Wound Care, Continence Care, Infusion Care and Ostomy Care. **What guidance did Convatec raise?** It raised full-year 2026 organic revenue growth guidance, excluding InnovaMatrix, to 6.25% to 7.0%, from 5.5% to 6.5% previously. **What is InnovaMatrix?** InnovaMatrix is a wound care treatment sold by Convatec. The company now expects it to generate only about $5 million of revenue in 2026, down from guidance of $5 million to $10 million. Sources: [AJ Bell](https://www.ajbell.co.uk/news/articles/convatec-shares-rise-increases-sales-outlook-growth-accelerates); [Convatec 10-month trading update, RNS via ADVFN](https://uk.advfn.com/stock-market/london/convatec-CTEC/share-news/Convatec-Group-PLC-Convatec-10-month-trading-updat/99732388).